


164. Louis-Sylvestre C, Clough K, Aseilam B, et al. Axillary treatment in conserva-
tive management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004;

165. Morrow M, Harris JR, Schaid DJ, et al. A randomized comparison of post-
operative radiotherapy with observation in breast cancer patients with posi-

dissection in women with invasive breast cancer and sentinel node metastas-
a randomized clinical trial. JAMA 2011;305:569–576.

167. Dangel TF, Van Zee KJ, King TA, et al. Axillary dissection can be avoided in

168. Rutgerson ED, Donker M, Shaver ME, et al. Radiotherapy or surgery of the
axilla after a positive sentinel node in breast cancer patients: Final analysis of
the EORTC AMAROS trial (1091822015). J Clin Oncol 2015;33:Abstr
1442. An inter-

postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:
980–980.

practice guidelines of the American Society of Clinical Oncology. J Clin


associated with large survival reduction after postmastectomy radiotherapy in
high-risk breast cancer: a subgroup analysis of DBCG-82 IDeC. Radiother
Oncol 2009;90:74–79.

173. Darby S. New results from the worldwide overview of individual patient data:
long-term follow-up of the randomised trials of radiotherapy. ASCO Annual


175. Poortmans P, Struikmans H, Kerkove C, et al. Irradiation of the internal mam-
mary and medial supraclavicular lymph nodes in stage I to III breast cancer:
10 years results of the EORTC Radiation Oncology and Breast Cancer
Groups phase III trial 22922/10295. Proceedings of the 2013 ECOG Confere-
ence. Abstract No. 2.

data from the randomised trials of radiotherapy. ASCO Annual Meeting

Oncology/College of American Pathologists guideline recommendations for
immunochemical testing of estrogen and progesterone receptors in breast

178. Olivoto IA, Bjeldj CD, Rudim PM, et al. Population-based validation of the pro-
23:2716–2725.

179. Kollias J, Elston CW, Ellis IO, et al. Early-onset breast cancer—histopatho-

logic features of the tumor and prognosis for patients with stage I or II breast
cancer: 10 years results of the EORTC Radiation Oncology and Breast Cancer
Groups phase III trial 22922/10295. Proceedings of the 2013 ECOG Confere-
ence. Abstract No. 2.

treatment effects in selected breast cancer subtypes of very young women

182. Piccart-Gebhart MJ. Anthracyclines and the tailoring of treatment for early

treatment subtypes in N9531 patients using the ASCO/CAP HER2 positivity

184. Braun S, Vogl FD, Ballman KV, et al. A pooled analysis of bone marrow micro-

of distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;

prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res

2817–2825.

using the 21-gene recurrence score in node-negative and node-positive metas-
mastatic patients with breast cancer treated with anastrozole or tamoxifen:

in women with node-negative, estrogen receptor-positive breast cancer.

the 21-gene recurrence score assay in postmenopausal women with node-
positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retro-


predictors for EB-positive breast cancer treated with adjuvant tamoxifen. Ann


dictant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;

sion associated with response to neoadjuvant chemotherapy in breast cancer.


197. Cancer Genome Atlas Network. Comprehensive molecular portraits of


